Tagged with Roche

China In May 2021 Swiss giant Roche launched the ‘Roche Accelerator’ in Shanghai, a USD 31.1 million investment aiming to foster and capitalise on China’s burgeoning life sciences start-up ecosystem.   The 5000 square metre project, Roche’s first such in-house accelerator globally, builds on the company’s sizeable existing R&D presence in…

Switzerland The Novartis and Roche names are synonymous with Swiss pharmaceutical innovation. But for these two Basel-based global behemoths, what value does Switzerland itself hold and what do they see as the areas in which they can truly bring value in their home market?   Roche – Driving Digital & Personalised…

India The latest from Indian pharma, including the year-to-year 51.5 percent growth of the pharma market in April, Lilly’s partnership with three generics makers to expand the availability of its arthritis drug baricitinib, Zydus Cadila’s upcoming approval of its COVID-19 vaccine, and the emergency use authorization for a COVID-19 antibody drug…

APAC COVID-19 has pushed diagnostics to the forefront of healthcare conversations across the world. Here, three leading lights from the Asia-Pacific medtech industry weigh in on what the new diagnostics paradigm might look like as the pandemic recedes.   Sanjay Prabhakaran, president Asia Pacific, Hologic “One positive outcome of this pandemic…

Singapore Regulatory harmonisation for medical devices between countries in Asia-Pacific has long been a challenging issue, predominantly due to the extreme variation in cultures, economic development, governmental models, and healthcare systems in the region.   Greater harmonisation would allow solutions introduced in APAC’s most developed markets to filter down to its…

Switzerland Thomas F. Schmidt, country manager of Roche Pharma in its home market of Switzerland discusses adjusting to his first role in general management, the particularities of the Swiss market, and how Roche is aiming to be a key player in Switzerland’s digitalisation push.   At Roche, we are looking at…

Asia-Pacific At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech market and, with a CAGR of nine percent, certainly its most dynamic. Chronic underfunding of healthcare systems in APAC means that a region accounting for 60 percent of the world’s population only represents a quarter of global…

Singapore Lance Little, managing director for Roche Diagnostics in Asia Pacific and board member of the Asia Pacific Medical Technology Association (APACMed), shares how COVID has affected their business in the region, his changing priorities during these challenging times, and the importance of building a unified culture across the regional organization,…

Norway Roche Diagnostics Norway’s Daniel Malarek discusses the resurgence of diagnostics in the wake of the COVID-19 pandemic, the Norwegian approval process for diagnostic tools, and the importance of stakeholder education.   Research shows that more than 70 percent of medical decision-making requires some form of diagnostics, yet less than 2…

Japan In 2020, Chugai Pharmaceutical Co. became Japan’s biggest drug company, driven by strong performance in recent years both from the company’s own drugs as well as those of parent company Roche. With Chugai now preparing for Phase III clinical trials for Roche’s Actemra for COVID-19, the company’s share price has…

Coronavirus During the fourth International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) COVID-19 media briefing, one thematic dominated: collaboration. With Eli Lilly chairman and CEO David Ricks, also president of IFPMA; Roche CEO Dr Severin Schwan, also vice-president of IFPMA; Pfizer chairman and CEO Dr Albert Bourla; MSD (Merck & Co.…

Long Read Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s zesty life science ecosystem. At first glance, the numbers certainly appear more steady than thrilling: a EUR 5.4 billion domestic…